Shares of Amgen were falling Tuesday after the biotechnology company easily beat quarterly earnings estimates and lifted revenue guidance.
Third-quarter sales of inflammation drug Amjevita/Amgevita rose 30% year-over-year, bolstered by 53% volume growth, partially offset by lower prices, according to the release, while sales of Prolia, one of Amgen’s general medicine treatments, jumped 14% from a year ago, boosted by a 7% uptick in volume and higher prices.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:
Colombia Últimas Noticias, Colombia Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Amgen’s stock jumps premarket after earnings beat and company again raises guidanceCiara Linnane is MarketWatch's investing- and corporate-news editor. She is based in New York.
Fuente: MarketWatch - 🏆 3. / 97 Leer más »
Arista Stock Jumps as Earnings Top EstimatesInvestors had worried about the outlook after Meta Platforms issued a more conservative capital-spending forecast than expected.
Fuente: MarketWatch - 🏆 3. / 97 Leer más »
Dow jumps more than 300 points ahead of Fed rate decision, earningsCertain parts of the economy have proved to be resilient, spurring concerns that the central bank could signal willingness to hold rates at their current level for longer than previously anticipate…
Fuente: nypost - 🏆 91. / 67 Leer más »